Table of Contents
Nanomedicine Market Overview
Nanomedicine, an interdisciplinary domain merging nanotechnology with medicine, offers innovative methods for diagnosing and treating diseases. By utilizing nanoparticles, typically ranging from 1 to 100 nanometers, nanomedicine facilitates precise drug delivery, accurate imaging, and advanced therapies like photothermal and gene treatments.
These nanoparticles play dual roles as diagnostic tools and therapeutic agents, assisting in early disease detection and personalized treatment while mitigating adverse effects.
Despite enduring challenges concerning safety, toxicity, and regulatory standards, ongoing progress in nanomedicine holds significant promise for transforming healthcare through customized, efficient, and minimally invasive interventions across various medical conditions.
Market Drivers
Several driving forces contribute to the growth of the global nanomedicine market. Nanotechnology advancements enhance treatment effectiveness, especially in creating new nanoparticles and drug delivery methods.
The rising incidence of chronic diseases and the desire for personalized medicine drive the adoption of nanomedicine—increased research and development investment, both in academia and the private sector, fosters innovation.
The aging population and interdisciplinary collaboration also play roles in market expansion. Additionally, the increasing use of nanomedicine in drug delivery, offering benefits like improved bioavailability and targeted treatment, shapes the market.
These factors collectively stimulate growth in the global nanomedicine market, providing substantial opportunities for advanced therapeutic and diagnostic technologies.
Market Size
The global nanomedicine market was valued at $139 billion in 2022 and is projected to reach $358 billion by 2032, with an anticipated highest compound annual growth rate (CAGR) of 10.2% between 2023 and 2032.
List of Major Companies
These are the top ten companies operating in the Nanomedicine Market:
- Abbott
- Merck
- Johnson-n-Johnson
- Nanobiotix
- Bristol-Myers-Squibb
- Teva
- Arrowhead
- Pfizer
- Mallinckrodt
- GE-Healthcare
Abbott
Company Overview
| Establishment Year | 1888 |
| Headquarter | Green Oaks, Illinois, U.S. |
| Key Management | Robert B. Ford (Chairman & CEO) |
| Revenue (US$ Bn) | $ 40.1 Billion (2023) |
| Headcount | ~ 114,000 (2023) |
| Website | http://abbott.com/ |
About Abbott Laboratories
Abbott Laboratories, a leading global healthcare company, is deeply involved in nanomedicine, utilizing its expertise in medical devices, diagnostics, and pharmaceuticals. Abbott focuses on pioneering nanotechnology in healthcare, particularly in improving drug delivery and diagnostics through nanoscale innovations.
By engineering nanoparticles for targeted drug delivery, Abbott aims to enhance treatment effectiveness while minimizing side effects. Additionally, Abbott develops advanced nanosensors and imaging agents for precise disease detection and monitoring.
Through collaboration with academic and industry partners, Abbott drives nanomedicine research and development, aiming to advance patient care and healthcare worldwide.
Geographical Presence
Abbott Laboratories has a widespread global presence, with facilities strategically located across various regions to serve its diverse markets. In North America, it operates manufacturing plants and offices in the United States, Canada, and Mexico.
In Europe, operations are in countries like Germany, France, Italy, and the United Kingdom. The company also has a growing presence in Asia, including China, Japan, India, and Australia.
Additionally, Abbott serves Latin America, Africa, and the Middle East with manufacturing facilities and sales offices. Abbott’s extensive global footprint reflects its commitment to advancing healthcare worldwide.
Recent Developments
- In March 2024, Abbott, Real Madrid, and the Real Madrid Foundation announced an extension of their partnership until the 2026-27 season. Under this extended agreement, Abbott will broaden its collaboration with the Real Madrid Foundation to offer nutrition education and screen for malnutrition among children enrolled in Real Madrid Foundation Social Sports Schools worldwide.
- In January 2024, Abbott got FDA approval for the Liberta RC DBS system, a rechargeable deep brain stimulation to treat movement disorders.
Merck
Company Overview
| Establishment Year | 1891 |
| Headquarter | Rahway, New Jersey, U.S. |
| Key Management | Robert M. Davis (Chairman, President and CEO) |
| Revenue (US$ Bn) | $ 60.1 B (2023) |
| Headcount | ~ 72,000 (2023) |
| Website | http://merck.com/ |
About Merck & Co
Merck & Co., Inc., a leading global pharmaceutical company, is an active nanomedicine pioneer. Utilizing its extensive pharmaceutical expertise, Merck harnesses nanotechnology to innovate therapeutic solutions across various medical fields.
Specifically, Merck explores nanomedicine’s potential in drug delivery, diagnostics, and targeted treatments to improve effectiveness and patient outcomes and address medical gaps.
Through strategic partnerships and ongoing research, Merck is a forefront innovator in nanomedicine, committed to advancing global healthcare and enhancing lives.
Geographical Presence
Merck & Co., Inc. maintains a global presence through strategically located facilities, including manufacturing plants, research centers, and commercial offices. With headquarters in the United States, Merck operates across North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East.
The company’s extensive network serves diverse markets and supports its mission of advancing healthcare worldwide.
Recent Developments
- In February 2024, Merck announced that the FDA had accepted a new supplemental Biologics License Application (sBLA) for priority review.
- In February 2024, Merck Animal Health confirmed the acquisition of Elanco Animal Health Incorporated’s aqua business through a definitive agreement.
Johnson-n-Johnson
Company Overview
| Establishment Year | 1886 |
| Headquarter | New Brunswick, New Jersey, US |
| Key Management | Joaquin Duato (Chairman & CEO) |
| Revenue (US$ Bn) | $ 85.1 Billion (2023) |
| Headcount | ~ 134,400 (2023) |
| Website | http://jnj.com/ |
About Johnson & Johnson
Johnson & Johnson, a global healthcare leader, actively explores nanomedicine applications, leveraging its expertise in pharmaceuticals, medical devices, and consumer health products. The company uses nanotechnology for drug delivery, diagnostics, imaging, and regenerative medicine.
Through partnerships and internal research, Johnson & Johnson aims to develop groundbreaking nanomedicine solutions to address medical gaps and enhance patient care. As an industry leader, Johnson & Johnson is dedicated to advancing nanomedicine and healthcare innovation.
Geographical Presence
Johnson & Johnson has a significant global presence, with operations spanning multiple continents. In North America, Johnson & Johnson has headquarters in the United States and operations covering the United States, Canada, and Mexico.
The company has facilities in countries like Germany, France, the United Kingdom, and Switzerland in Europe. Similarly, Johnson & Johnson operates in the Asia-Pacific region in China, Japan, India, Australia, and Singapore.
Additionally, the company serves Latin America, Africa, and the Middle East, ensuring access to healthcare products and services across these regions. Overall, Johnson & Johnson’s extensive global footprint reflects its commitment to improving health and well-being globally.
Recent Development
- In February 2024, Johnson & Johnson disclosed FDA approval for RYBREVANT, in combination with chemotherapy, as the initial treatment for patients with NSCLC.
- In January 2024, Johnson & Johnson entered a definitive agreement to purchase Ambrx Biopharma, Inc., a biopharmaceutical company.
Nanobiotix
Company Overview
| Establishment Year | 2003 |
| Headquarter | Paris, France |
| Key Management | Laurent Levy (CEO) |
| Revenue (US$ Bn) | $303.4 Million (2022) |
| Headcount | ~ 101 (2022) |
| Website | http://nanobiotix.com/ |
About Nanobiotix
Nanobiotix SA specializes in nanomedicine, focusing on developing nanoparticle-based therapies for cancer treatment. Utilizing its proprietary NanoXray technology, Nanobiotix aims to enhance the efficacy of cancer therapies while minimizing side effects.
The company’s innovative approach involves leveraging nanoparticles to amplify the impact of radiation therapy selectively within the tumor, thus improving treatment outcomes. Nanobiotix’s research and development efforts in nanomedicine are centered on advancing personalized cancer treatment options and addressing unmet medical needs in oncology.
Through strategic partnerships and ongoing clinical trials, Nanobiotix is committed to driving innovation in nanomedicine and improving patient care in cancer treatment.
Geographical Presence
Nanobiotix SA has a global presence, with operations and activities spanning various regions worldwide. The company’s headquarters are in Paris, France, serving as a hub for its research, development, and corporate functions.
Additionally, Nanobiotix has established strategic partnerships and collaborations with academic institutions, research organizations, and biopharmaceutical companies across Europe, North America, Asia-Pacific, and other regions.
Through these partnerships, Nanobiotix expands its geographical footprint and enhances its capabilities in advancing nanomedicine solutions for cancer treatment globally.
Recent Development
- In December 2023, NANOBIOTIX announced that its partner, LianBio, had reached an agreement with Janssen Pharmaceuticals, a Johnson & Johnson subsidiary. Under the deal, LianBio has transferred its exclusive rights to develop and market the potential first-in-class radio enhancer NBTXR3 to Janssen in China, South Korea, Singapore, and Thailand.
- In July 2023, NANOBIOTIX revealed a licensing agreement for the global co-development and commercialization of the potential groundbreaking radio enhancer NBTXR3.
Bristol-Myers-Squibb
Company Overview
| Establishment Year | 1887 |
| Headquarter | Princeton, New Jersey, U.S. |
| Key Management | Chris Boerner (CEO) |
| Revenue (US$ Bn) | $45.01 B (2023) |
| Headcount | ~ 34,100 (2023) |
| Website | http://bms.com/ |
About Bristol Myers Squibb
Bristol Myers Squibb is a prominent nanomedicine player, leveraging its pharmaceutical and biotechnology expertise. The company utilizes nanotechnology to develop innovative therapies for various medical conditions.
Specifically, Bristol Myers Squibb explores the application of nanomedicine in drug delivery, diagnostics, imaging, and targeted therapies. Through strategic collaborations and internal research initiatives, the company aims to develop novel nanomedicine solutions to address unmet medical needs and improve patient outcomes.
As a leading healthcare company, Bristol Myers Squibb remains committed to advancing nanomedicine and driving innovation in healthcare.
Geographical Presence
Bristol Myers Squibb has a significant global presence across multiple continents, strategically serving diverse markets. North America’s US headquarters manages operations in the US, Canada, and Mexico, addressing domestic and international needs.
The company operates manufacturing facilities, research hubs, and European offices in Germany, France, the UK, and Switzerland. Similarly, it is expanding in the Asia-Pacific region with operations in China, Japan, India, Australia, and Singapore.
Bristol Myers Squibb also caters to Latin America, Africa, and the Middle East, ensuring accessibility to its healthcare offerings. Overall, its broad global footprint underscores its commitment to enhancing healthcare worldwide.
Recent Developments
- In February 2024, Bristol Myers Squibb finalized the purchase of RayzeBio, enhancing its portfolio with a unique Actinium-based radiopharmaceutical platform.
- In February 2024, Bristol Myers disclosed two regulatory approvals for Opdivo used alongside chemotherapy before surgery and for Opdivo as a post-surgery treatment for resectable stage IIA to IIIB NSCLC.
Teva
Company Overview
| Establishment Year | 1901 |
| Headquarter | Tel Aviv, Israel |
| Key Management | Richard Francis (President and CEO) |
| Revenue (US$ Bn) | $ 15.8 Billion (2023) |
| Headcount | ~ 35,000 (2023) |
| Website | http://www.tevapharm.com/ |
About Teva Pharmaceuticals
Teva Pharmaceuticals is actively involved in nanomedicine, leveraging its pharmaceutical and drug-delivery technologies expertise. The company focuses on utilizing nanotechnology to enhance the efficacy and safety of drug formulations.
Specifically, Teva explores the application of nanomedicine in targeted drug delivery, improving bioavailability and reducing side effects. Through research and development initiatives, Teva aims to develop innovative nanomedicine solutions for various therapeutic areas, addressing unmet medical needs and improving patient outcomes.
As a global leader in the pharmaceutical industry, Teva remains committed to advancing nanomedicine and delivering cutting-edge healthcare solutions to patients worldwide.
Geographical Presence
Teva Pharmaceuticals has a global presence, with operations spanning North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East. Teva has headquarters in the United States and operations in Canada and Mexico in North America.
The company has facilities in Germany, France, the United Kingdom, and Italy in Europe. Teva’s presence in the Asia-Pacific region includes countries like China, Japan, India, and Australia.
Additionally, the company serves Latin America, Africa, and the Middle East through manufacturing facilities and distribution centers. Teva’s extensive global footprint reflects its commitment to providing healthcare products and services.
Recent Developments
- In February 2024, Teva partnered with Nhwa Pharmaceutical to market and distribute AUSTEDO, a therapy for neurodegenerative and movement disorders like tardive dyskinesia and Huntington’s disease-related chorea in adults.
- In January 2024, Teva plans to sell its active pharmaceutical ingredient (API) business, known as “TAPI,” to optimize revenue and redirect resources towards growth and innovation, ultimately enhancing patient care.
Arrowhead
Company Overview
| Establishment Year | 2004 |
| Headquarter | Pasadena, California, U.S. |
| Key Management | Christopher Richard Anzalone (CEO) |
| Revenue (US$ Bn) | $ 243.2 Million (2022) |
| Headcount | ~ 376 (2022) |
| Website | http://arrowheadpharma.com/ |
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is at the forefront of nanomedicine, specializing in developing RNA interference (RNAi) therapeutics. Utilizing nanotechnology, the company delivers RNAi-based drugs to target disease-causing genes selectively.
By encapsulating RNA molecules in lipid nanoparticles, Arrowhead can silence these genes, offering novel treatment options for various medical conditions. The company’s dedication to advancing nanomedicine is evident in its robust pipeline of RNAi therapeutics, which target both liver and extrahepatic diseases.
Through strategic partnerships and ongoing research, Arrowhead aims to leverage nanotechnology to enhance patient outcomes and address unmet medical needs.
Geographical Presence
Arrowhead Pharmaceuticals has a global presence, with operations spanning various regions worldwide. The company’s headquarters are located in Pasadena, California.
Additionally, Arrowhead has established strategic partnerships and collaborations with academic institutions, research organizations, and biopharmaceutical companies across North America, Europe, Asia-Pacific, and other regions.
Arrowhead expands its geographical footprint through these partnerships and enhances its capabilities in advancing RNA interference (RNAi) therapeutics for treating various diseases.
Recent Developments
- In December 2023, Arrowhead Pharmaceuticals applied for regulatory clearance in New Zealand to start a Phase I/IIA clinical study for ARO-CFB to treat complement-mediated renal disease.
- In November 2023, GSK and Arrowhead Pharmaceuticals partnered to acquire exclusive global rights for developing and commercializing JNJ-3989, a product from Johnson & Johnson’s Janssen Pharmaceuticals.
Pfizer
Company Overview
| Establishment Year | 1849 |
| Headquarter | New York City, U.S. |
| Key Management | Albert Bourla (CEO) |
| Revenue (US$ Bn) | $ 58.5 Billion (2023) |
| Headcount | ~ 88,000 (2023) |
| Website | http://pfizer.com/ |
About Pfizer
Pfizer Inc. is actively engaged in the field of nanomedicine, focusing on the development of innovative therapies and drug delivery systems. Leveraging nanotechnology, Pfizer aims to enhance the efficacy and safety of its pharmaceutical products.
The company explores the application of nanomedicine in various therapeutic areas, including oncology, immunology, and infectious diseases. Pfizer’s research and development efforts in nanomedicine involve the utilization of nanoparticles for targeted drug delivery, improving bioavailability, and reducing side effects.
Through strategic partnerships and collaborations, Pfizer seeks to advance the development of nanomedicine solutions to address unmet medical needs and improve patient outcomes.
Geographical Presence
Pfizer Inc. has a widespread global presence, headquartered in New York City, USA. The company operates across multiple continents, with manufacturing facilities, research centers, and commercial offices strategically located in key regions worldwide.
In North America, Pfizer has a significant presence, while in Europe, it has operations in countries such as the UK, Germany, France, and Italy. The company also has a growing footprint in the Asia-Pacific region, including China, Japan, India, Australia, and Singapore.
Additionally, Pfizer serves Latin America, Africa, and the Middle East through various facilities and offices. Pfizer’s extensive geographical reach underscores its dedication to improving healthcare globally through innovative solutions.
Recent Development
- In December 2023, Pfizer successfully acquired Seagen Inc., a global biotech company specializing in groundbreaking cancer treatments.
- In September 2023, Pfizer and BioNTech SE received FDA approval for their COVID-19 vaccine, Omicron XBB.1.5-adapted, for individuals aged 12 and older. Emergency use authorization was also granted for children aged six months to 11 years.
Mallinckrodt
Company Overview
| Establishment Year | 1867 |
| Headquarter | Dublin, Ireland |
| Key Management | Sigurdur (Siggi) Olafsson (CEO) |
| Revenue (US$ Bn) | $ 2.2 Billion (2021) |
| Headcount | ~ 2,800 (2021) |
| Website | http://mallinckrodt.com/ |
About Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals is actively involved in the field of nanomedicine, focusing on the development of innovative therapies and drug delivery systems. Leveraging nanotechnology, Mallinckrodt aims to enhance the efficacy and safety of its pharmaceutical products.
The company explores the application of nanomedicine in various therapeutic areas, including pain management, autoimmune diseases, and central nervous system disorders.
Mallinckrodt’s research and development efforts in nanomedicine involve the utilization of nanoparticles for targeted drug delivery, improving bioavailability, and reducing side effects.
Through strategic partnerships and collaborations, Mallinckrodt seeks to advance the development of nanomedicine solutions to address unmet medical needs and improve patient outcomes.
Geographical Presence
Mallinckrodt Pharmaceuticals operates globally, headquartered in Staines-upon-Thames, United Kingdom. With a significant presence in North America, the company serves patients across the United States and Canada, spanning various states and provinces.
Mallinckrodt has manufacturing facilities and commercial offices in Europe in countries like Ireland, Germany, and France. Additionally, the company has a foothold in the Asia-Pacific region, including Australia and Japan.
Mallinckrodt also extends its reach to Latin America, Africa, and the Middle East through partnerships and collaborations. Mallinckrodt Pharmaceuticals’ global presence underscores its commitment to delivering innovative healthcare solutions worldwide.
Recent Developments
- In October 2023, Mallinckrodt plc’s Plan of Reorganization was approved by the U.S. Bankruptcy Court for the District of Delaware, paving the way for the company to exit Chapter 11 bankruptcy by year-end.
- In September 2023, Mallinckrodt updated the label for StrataGraft in collaboration with the FDA, removing specific xenotransplantation-related requirements deemed unnecessary for the product’s commercial distribution.
GE-Healthcare
Company Overview
| Establishment Year | 1994 |
| Headquarter | Chicago, Illinois, U.S. |
| Key Management | Peter Arduini (CEO) |
| Revenue (US$ Bn) | $ 19.5 Billion (2023) |
| Headcount | ~ 51,000 (2023) |
| Website | http://gehealthcare.com/ |
About GE Healthcare
GE Healthcare is actively engaged in nanomedicine, utilizing its healthcare technology and innovation expertise to develop advanced medical imaging and diagnostic solutions incorporating nanotechnology.
The company focuses on enhancing medical diagnosis, monitoring, and treatment accuracy and efficiency through nanomedicine. GE Healthcare’s R&D efforts in this field include creating nanoparticle-based contrast agents for MRI, CT scans, and ultrasound. Moreover, GE Healthcare explores nanomaterials for targeted drug delivery and personalized medicine.
Collaborating with academic institutions, research organizations, and healthcare providers, GE Healthcare strives to advance nanotechnology in healthcare, aiming to improve patient outcomes and healthcare delivery.
Geographical Presence
GE Healthcare operates globally, headquartered in Chicago, Illinois. The company has a significant presence in North America, with operations covering various states in the United States and serving patients across Canada.
In Europe, GE Healthcare has manufacturing facilities and commercial offices in countries like the United Kingdom, Germany, France, and Italy. Additionally, the company has a strong presence in the Asia-Pacific region, including countries such as China, Japan, India, Australia, and Singapore.
Through partnerships and collaborations, GE Healthcare also serves Latin America, Africa, and the Middle East. GE Healthcare’s extensive global footprint reflects its commitment to delivering innovative healthcare solutions worldwide.
Recent Developments
- In February 2024, GE Healthcare implemented the Revolution Apex platform and Omni Legend digital PET/CT system at Virtua Health’s cardiology facility in Moorestown, New Jersey.
- In February 2024, GE Healthcare and Biofourmis partnered strategically to improve continuity of care by providing safe, effective, and accessible home-based care, extending support beyond hospital settings. This collaboration utilizes the expertise of both companies to scale and deliver innovative home care solutions.
Discuss Your Needs With Our Analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
